For example, the artificially synthesized peptide AP8, designed using this approach and capable of specifically binding to FGF1, can block the activation of the ERK1/2 and AKT signaling pathways in breast cancer cells and vascular endothelial cells induced by FGF1. This evidence concerns the gene FGF1 and breast carcinoma.